2. Apoptosis Immunology/Inflammation
  3. TNF Receptor Apoptosis Interleukin Related Caspase
  4. Golimumab

Golimumab  (Synonyms: CNTO-148)

Cat. No.: HY-P99111 Purity: 99.68%
COA

Molarity Calculator

Golimumab (CNTO-148) is a potent human IgG1 TNFα antagonist monoclonal antibody. Golimumab has anti-inflammation activitity and inhibits IL-6 and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cell apoptosis. Golimumab can be used for rheumatoid arthritis, Crohn's disease and cancer research.

For research use only. We do not sell to patients.

Golimumab Chemical Structure

Golimumab Chemical Structure

CAS No. : 476181-74-5

Size Price Stock Quantity
1 mg USD 370 In-stock
5 mg USD 850 In-stock
10 mg   Get quote  
50 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Golimumab Related Antibodies

Top Publications Citing Use of Products

View All Caspase Isoform Specific Products:

View All Isoforms
Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Golimumab (CNTO-148) is a potent human IgG1 TNFα antagonist monoclonal antibody. Golimumab has anti-inflammation activitity and inhibits IL-6 and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cell apoptosis. Golimumab can be used for rheumatoid arthritis, Crohn's disease and cancer research[1][2][3].

IC50 & Target[1]

IL-1

 

IL-6

 

CD40

 

In Vitro

Golimumab (CNTO-148) (0.1-10 μg /mL; 24-72 hours; transmembrane TNFα–transfected Jurkat cells) induces reductions in the viability of transmembrane TNFα–expressing cells[1].
Golimumab (CNTO-148) (10 μg /mL; 48 hours; transmembrane TNFα–transfected Jurkat cells) induces apoptosis, increase the levels of active caspase-3 and induces apoptotic DNA fragmentation[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Golimumab Related Antibodies

Cell Viability Assay[1]

Cell Line: Transmembrane TNFα–transfected Jurkat cells
Concentration: 0.1, 1 and 10 μg/mL
Incubation Time: 24, 48 and 72 hours
Result: Reduced cell viability in a dose- and time-dependent manner.

Apoptosis Analysis[1]

Cell Line: Transmembrane TNFα–transfected Jurkat cells
Concentration: 10 μg /mL
Incubation Time: 48 hours
Result: Had the percentage of apoptotic cells for 30.29%.

Western Blot Analysis[1]

Cell Line: Transmembrane TNFα–transfected Jurkat cells
Concentration: 10 μg /mL
Incubation Time: 48 hours
Result: Increased the levels of active caspase-3 and induces apoptotic DNA fragmentation.
In Vivo

Golimumab (CNTO-148) (24 mg/kg; i.h.; daily, for 7 days; swiss-albino healthy male mice) inhibits oxidative stress, apoptotic cell death inflammatory response, thus improving renal function. Golimumab reduces all markers of kidney injury and attenuates cell death[2].
Golimumab (CNTO-148) (1-10 mg/kg; i.p.;daily; for 4 weeks; Tg197 transgenic mouse model) relieves TNFα-induced arthritis in a mouse model of human[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Swiss-albino healthy male mice[2]
Dosage: 24 mg/kg
Administration: Subcutaneous injection; daily, for 7 days
Result: Reduced serum parameters like BUN, NGAL creatinine, cystatin C, and urinary parameters like KIM-1, NAG, albumin clusterin.
Animal Model: Swiss-albino healthy male mice[2]
Dosage: 24 mg/kg
Administration: Subcutaneous injection; daily, for 7 days
Result: Inhibited oxidative stress, reduces MDA concentrations and increases the GSH and catalase levels.
Animal Model: Swiss-albino healthy male mice[2]
Dosage: 24 mg/kg
Administration: Subcutaneous injection; daily, for 7 days
Result: Inhibitd cisplatin-induced inflammation, decreased TNF-α, including IL-6, IL-1β, MCP-1, ICAM-1, and TGF-β1 levels and increases IL-10 concentrations, reduced caspase 3 in cisplatin injected mice kidneys.
Animal Model: Tg197 transgenic mouse model[3]
Dosage: 1 and 10 mg/kg
Administration: Intraperitoneal injection;for 4 weeks
Result: Reduced the arthritic index.
Clinical Trial
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Golimumab]
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation

Purity: 99.68%

COA (291 KB)

Handling Instructions (2659 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Golimumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Golimumab476181-74-5CNTO-148CNTO148CNTO 148TNF ReceptorApoptosisInterleukin RelatedCaspaseTumor Necrosis Factor ReceptorTNFRILapoptosisTNFαanticanceranti- inflammation cytokinesInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Golimumab
Cat. No.:
HY-P99111
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.